Engineered Mesenchymal Stem Cells Expressing CD::UPRT and TRAIL Exhibit Potent Anti-Tumor Effects in Glioblastoma Patient-Derived Organoids
Cells · 2026
DOI: 10.3390/cells15171620 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Dokyeong Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Glioblastoma, Organoids, TNF-Related Apoptosis-Inducing Ligand. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Glioblastoma (GBM) is a highly aggressive brain tumor with limited therapeutic options due to its invasive nature, therapeutic resistance, and the challenge of drug delivery across the blood–brain barrier (BBB). Mesenchymal stem cells (MSCs), owing to their tumor tropic properties and ability to cross the BBB, offer a promising platform for targeted anti-cancer delivery. We previously engineered MSCs to express CD::UPRT and TRAIL, along with chemokine receptors to enhance tumor homing (MSC-CD-TRAIL; BM03). This study evaluated the anti-tumor efficacy of BM03 using GBM patient-derived organoids (GBOs), clinically relevant in vitro models. Using a GBO–MSC co-culture system, BM03 significantly increased cell death and reduced viability in GBOs from four GBM patients compared with controls and MSC-WT groups. In 3D invasion assays, BM03-treated GBOs showed markedly reduced invasive outgrowth, accompanied by downregulation of EMT markers (Zeb1 and Snail) and stem-like markers (Olig2 and Sox2), particularly in invasive regions. GFAP expression remained unchanged, suggesting selective targeting of tumor stem-like cells. Live-cell imaging further demonstrated BM03 infiltration into GBOs, which was associated with increased apoptosis, as evidenced by elevated cleaved caspase-3 levels. These findings provide organoid-based preclinical evidence supporting further evaluation of BM03 as an MSC-based therapeutic strategy for GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
- Precision Medicine Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
- Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
- Department of Neurosurgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
- Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
ORCID-Profile: Dokyeong Kim, Junseong Park, Stephen Ahn, Yeun-Jun Chung
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kim, D., Park, M., Park, J., Park, S. A., Ahn, S., & Chung, Y. J. (2026). Engineered Mesenchymal Stem Cells Expressing CD::UPRT and TRAIL Exhibit Potent Anti-Tumor Effects in Glioblastoma Patient-Derived Organoids. Cells. https://doi.org/10.3390/cells15171620
Vancouver
Kim D, Park M, Park J, Park SA, Ahn S, Chung YJ. Engineered Mesenchymal Stem Cells Expressing CD::UPRT and TRAIL Exhibit Potent Anti-Tumor Effects in Glioblastoma Patient-Derived Organoids. Cells. 2026. doi:10.3390/cells15171620
BibTeX
@article{Kim2026,
author = {Kim, Dokyeong and Park, Minyoung and Park, Junseong and Park, Soon A and Ahn, Stephen and Chung, Yeun-Jun},
title = {Engineered Mesenchymal Stem Cells Expressing CD::UPRT and TRAIL Exhibit Potent Anti-Tumor Effects in Glioblastoma Patient-Derived Organoids},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15171620}
}
EUVIMED